Hydroxyprogesterone Caproate
Makena
Half-life
7.8 days
Time to Peak
3 days
Steady State
~39 days
Dose Range
250–250 mg
Frequency
Weekly
Overview
Long-acting injectable synthetic progestogen. Primarily indicated for prevention of preterm birth in high-risk pregnancies. Half-life of approximately 7.8 days (187h). Note: FDA withdrew accelerated approval for Makena in 2023 after confirmatory trial did not verify clinical benefit, but the compound remains available from compounding pharmacies.
Mechanism of Action
Synthetic progestogen with long-acting depot properties due to the caproate ester. Acts on progesterone receptors to support uterine quiescence.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Intramuscular (IM) | 250–250 mg | 7.8 days | 3 days | Weekly |
Used in Regimens
Hydroxyprogesterone Caproate is not currently part of any catalog regimen.
Data Sources
- FDA Label Makena (hydroxyprogesterone caproate) FDA Prescribing Information
Related Tools
Track Hydroxyprogesterone Caproate with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.